🇺🇸 FDA
Pipeline program

Almonertinib

FUSCC-20230323

Phase 3 small_molecule active

Quick answer

Almonertinib for Non-small Cell Lung Cancer Metastatic is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Non-small Cell Lung Cancer Metastatic
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials